Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas.

@article{Nyman2009Bcl2BN,
  title={Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas.},
  author={Heidi Nyman and Mats Jerkeman and Marja-Liisa Karjalainen-Lindsberg and Alison H Banham and Gunilla Enblad and Sirpa Lepp{\"a}},
  journal={European journal of haematology},
  year={2009},
  volume={82 5},
  pages={364-72}
}
OBJECTIVES Non-germinal center (non-GC) phenotype, high level expression of the transcription factor forkhead box protein P1 (FOXP1) and anti-apoptotic protein Bcl-2 have been identified as unfavorable prognostic factors for diffuse large B-cell lymphoma (DLBCL) patients treated with chemotherapy. Our aim was to re-evaluate the prognostic impact of these… CONTINUE READING